Gut microbiota metabolites have a great influence on host digestive function and body health itself. The effects of intestinal microbes on the host metabolism and nutrients absorption are mainly due to regulatory mechanisms related to serotonin, cytokines, and metabolites. Multiple studies have repeatedly reported that the gut microbiota plays a fundamental role in the absorption of bioactive compounds by converting dietary polyphenols into absorbable bioactive substances. Moreover, some intestinal metabolites derived from natural polyphenol products have more biological activities than their own fundamental biological functions. Bioactive like polyphenolic compounds, prebiotics and probiotics are the best known dietary strategies for regulating the composition of gut microbial populations or metabolic/immunological activities, which are called “three “p” for gut health”. Intestinal microbial metabolites have an indirect effect on atherosclerosis, by regulating lipid metabolism and inflammation. It has been found that the diversity of intestinal microbiota negatively correlates with the development of atherosclerosis. The fewer the variation and number of microbial species in the gut, the higher the risk of developing atherosclerosis. Therefore, the atherosclerosis can be prevented and treated from the perspective of improving the number and variability of gut microbiota. In here, we summarize the effects of gut metabolites of natural products on the pathological process of the atherosclerosis, since gut intestinal metabolites not only have an indirect effect on macrophage foaming in the vessel wall, but also have a direct effect on vascular endothelial cells.

Diabetes mellitus is a pervasive global health crisis, with type 2 diabetes (T2D) representing the majority of cases. While conventional pharmacological therapies exist, suboptimal efficacy, adverse effects, and inadequate glycemic control in a substantial proportion of patients highlight the need for complementary strategies. There is growing scientific and clinical interest in plant-based functional foods, including Ribes nigrum L. (blackcurrant), which is rich in bioactive phytochemicals such as anthocyanins, flavonols, and phenolic acids. This review evaluates the antidiabetic and metabolic regulatory potential of blackcurrant, focusing on its multi-target mechanisms of action. Available experimental evidence suggests that blackcurrants may influence glucose metabolism through several mechanisms, including inhibition of carbohydrate-digesting enzymes (α-amylase and α-glucosidase), modulation of intestinal glucose transporters (SGLT1 and GLUT2), and potential modulation of insulin sensitivity involving AMPK signaling and GLUT4 translocation. In addition, blackcurrant constituents may stimulate glucagon-like peptide-1 (GLP-1) secretion, modulate gut microbiota composition, and exert antioxidant and anti-inflammatory effects that counteract key drivers of insulin resistance and β-cell dysfunction. Supporting human studies indicate that blackcurrant consumption has been associated with attenuation of postprandial glycemic and insulinemic responses and modest improvements in cardiometabolic biomarkers, although findings remain limited by study size, duration, and formulation heterogeneity. Overall, Ribes nigrum represents a promising dietary adjunct for the prevention and management of T2D through multi-target metabolic regulation.